Nektar Therapeutics
NKTR
Delayed Nasdaq - 04/25 10:00:00 pm
82.59USD
-2.27%
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Researches and develops inhalation drug delivery systems

Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms.

Its products contain drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology.

The company provides small molecule drugs, peptides and other potential biologic drug candidates.

It's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, CA.

Number of employees : 509 persons.
Sales per Businesses
20162017
USD
(in Million)
%USD
(in Million)
%
License, Collaboration and Other60.3836.5%210.9768.6%
Product55.3533.5%32.6910.6%
Non-cash Royalty Revenue Related to Sale of Future Royalties30.1618.2%30.539.9%
Royalty19.5411.8%33.5310.9%
Sales per Regions
20162017
USD
(in Million)
%USD
(in Million)
%
Europe126.2976.3%116.9038%
United States39.1523.7%190.8162%
Germany and Netherlands----
All Other Countries----
India----
Shareholders
- PRIMECAP Management Co.13.9%
- BlackRock Fund Advisors12.5%
- The Vanguard Group, Inc.10.4%
- OppenheimerFunds, Inc.9.08%
- Fidelity Management & Research Co.6.96%
- SSgA Funds Management, Inc.2.47%
Managers
- President, Chief Executive Officer & Director :
    Howard Robin
- Chairman :
    Robert Chess
- Chief Operating Officer & Senior Vice President :
    John Nicholson
- Chief Financial Officer & Senior Vice President :
    Gilbert Labrucherie
- Chief Research & Development Officer :
    Stephen Doberstein
- Chief Medical Officer & Senior VP-Drug Development :
    Ivan Gergel
- Chief Medical Officer & SVP-Clinical Development :
    Mary Tagliaferri
- Chief Scientific Officer & Senior VP-Research :
    Jonathan Zalevsky
- Independent Director :
    Christopher Kuebler
- Independent Director :
    Roy Whitfield
Company contact information
Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco, CA 94158

Phone : +1.415.482.5300
Fax : +1.415.339.5300
Web : www.nektar.com
Overall rating
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision